Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The In Vitro Evaluation of Modifications in CPD‐Adenine Anticoagulated‐Preserved Blood at Various Hematocrits

The In Vitro Evaluation of Modifications in CPD‐Adenine Anticoagulated‐Preserved Blood at Various... Erythrocytes stored in the new CPD‐adenine anticoagulant (CPDA‐1) barely met the 70 per cent 24‐hour postinfusion 51Cr recoveries on day 35 when stored at hematocrit ≥ 75 per cent. CPDA‐1 differs from CPD in that it has 1.25 times the glucose concentration plus 17.3 mg adenine/63 ml. In an effort to improve the survivability (or viability) of red blood cells following extended storage (35+ days), two new CPD‐adenine anticoagulants have been tested in vitro. CPDA‐2 and CPDA‐3 (both of which contain 34.6 mg/63 ml of anticoagulant or 0.50 mM adenine [final Mood concentration], and either 1.75 times or 2.0 times respectively the amount of glucose used in CPD) have been tested for whole blood or red blood cell storage to 42 days. Red blood cell ATP concentrations were better maintained throughout 42 days of storage in both of these formulations than in CPDA‐1 at hematocrits that ranged from 40 to 85. Other biochemical parameters (2,3‐DPG, pH, plasma hemoglobin) were similar to those of blood stored in CPD or CPDA‐1. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Transfusion Wiley

The In Vitro Evaluation of Modifications in CPD‐Adenine Anticoagulated‐Preserved Blood at Various Hematocrits

Transfusion , Volume 20 (4) – Jan 8, 1980

Loading next page...
 
/lp/wiley/the-in-vitro-evaluation-of-modifications-in-cpd-adenine-anticoagulated-ecRopIw0IY

References (19)

Publisher
Wiley
Copyright
Copyright © 1980 Wiley Subscription Services
ISSN
0041-1132
eISSN
1537-2995
DOI
10.1046/j.1537-2995.1980.20480260273.x
Publisher site
See Article on Publisher Site

Abstract

Erythrocytes stored in the new CPD‐adenine anticoagulant (CPDA‐1) barely met the 70 per cent 24‐hour postinfusion 51Cr recoveries on day 35 when stored at hematocrit ≥ 75 per cent. CPDA‐1 differs from CPD in that it has 1.25 times the glucose concentration plus 17.3 mg adenine/63 ml. In an effort to improve the survivability (or viability) of red blood cells following extended storage (35+ days), two new CPD‐adenine anticoagulants have been tested in vitro. CPDA‐2 and CPDA‐3 (both of which contain 34.6 mg/63 ml of anticoagulant or 0.50 mM adenine [final Mood concentration], and either 1.75 times or 2.0 times respectively the amount of glucose used in CPD) have been tested for whole blood or red blood cell storage to 42 days. Red blood cell ATP concentrations were better maintained throughout 42 days of storage in both of these formulations than in CPDA‐1 at hematocrits that ranged from 40 to 85. Other biochemical parameters (2,3‐DPG, pH, plasma hemoglobin) were similar to those of blood stored in CPD or CPDA‐1.

Journal

TransfusionWiley

Published: Jan 8, 1980

There are no references for this article.